Silo Pharma Secures U.S. Patent Allowance for PTSD Therapeutic SPC-15, Bolstering Intellectual Property Strategy

Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering its lead intranasal therapeutic, SPC-15, aimed at treating post-traumatic stress disorder. The patent, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior," encompasses both composition and method claims for Silo's proprietary approach to preventing or delaying stress-induced behavioral responses. This U.S. allowance follows a corresponding patent issued by the Japan Patent Office earlier this year, signaling growing global recognition of the company's innovative work in stress-induced psychiatric disorders.

The significance of this patent allowance lies in its potential to provide Silo Pharma with a competitive edge in the burgeoning field of PTSD therapeutics. A Notice of Allowance indicates that the USPTO has completed its examination and determined that the application meets the requirements for patentability, meaning the patent will be granted shortly. For Silo, this strengthens its intellectual property portfolio, which is crucial for attracting investment and partnerships as it advances SPC-15 through clinical development. The patent protection could also help the company secure market exclusivity upon approval, allowing it to recoup research and development costs and maximize commercial potential.

PTSD represents a significant unmet medical need, affecting millions of people worldwide. Current treatments often have limitations, including side effects and variable efficacy. SPC-15's intranasal delivery and novel mechanism of action could offer a more effective and patient-friendly option. By targeting stress-induced fear, depressive-like, and anxiety-like behaviors, SPC-15 aims to address core symptoms of PTSD. The patent allowance not only validates the scientific rationale behind SPC-15 but also positions Silo as a key player in the development of next-generation psychiatric therapies.

This development is part of Silo Pharma's broader strategy to build a diversified portfolio of therapeutic assets. The company focuses on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis. Collaborations with leading universities and laboratories underscore Silo's commitment to cutting-edge research. The addition of this U.S. patent allowance to its portfolio of issued and allowed patents enhances the company's credibility and could facilitate future licensing deals or strategic alliances.

Investors and industry observers will be watching closely as Silo progresses SPC-15 through the regulatory pathway. The patent allowance is a critical milestone that de-risks the program and may accelerate timelines. For the full press release, visit https://ibn.fm/Hh4Z6. More information about Silo Pharma is available at silopharma.com. The latest news and updates relating to SILO can be found in the company's newsroom at https://ibn.fm/SILO.